logo

Biotechnology & Drugs News

Share

Novartis Acquires Exclusive Global Development And Marketing Rights To MOR106

Novartis Q2 Core EPS $1.29 Vs $1.22 Last Year

Silence Therapeutics Appoints David Horn Solomon As CEO